ArticleMetabolic brain disease2026
Hepatic-targeted low-intensity pulsed ultrasound attenuates cerebral amyloidosis via upregulating insulin-degrading enzyme.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study aimed to investigate whether low-intensity pulsed ultrasound (LIPUS) targeted at the liver can alleviate cerebral Aβ pathology by improving peripheral metabolism and enhancing hepatic Aβ clearance in a comorbid mouse model. 5xFAD transgenic mice were fed a high-fat diet (HFD) to induce peripheral IR. Mice received hepatic LIPUS intervention for four weeks. Outcomes were assessed using metabolic tests, in vivo and ex vivo fluorescence imaging of Aβ trafficking, neuropathological analysis, proteomics, and the Morris water maze. LIPUS ameliorated HFD-induced IR, hepatic steatosis, and pancreatic islet hyperplasia. It upregulated hepatic expression of Aβ-clearance proteins (IDE, LRP-1), enhanced peripheral Aβ catabolism, and reduced Aβ infiltration into the brain. Consequently, LIPUS attenuated cerebral Aβ deposition, neuronal apoptosis, and partially rescued spatial learning and memory deficits. Proteomic analysis confirmed systemic upregulation of metabolic and clearance pathways. Hepatic LIPUS modulates the peripheral metabolism-central clearance axis, reducing brain Aβ burden and improving cognitive function. This non-invasive approach presents a novel strategy for AD, particularly in the context of metabolic dysfunction.
Indexed as
Identifiers
42678559What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.